|
Market Closed -
Nasdaq
16:30:00 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 1.530 USD | -2.55% |
|
+5.52% | -77.16% |
| 25-09-11 | GRI Bio Says Data Show No Lung Function Decline in Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis | MT |
| 25-04-01 | GRI Bio Prices up to $13 Million Equity Offering | MT |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GRI | Delayed |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 5.95 | 5.95 | 7 |
| Spread/Res. | -74.29% | -74.29% | -78.14% |
| Spread/Supp. | +78.40% | +78.40% | +13.65% |
| Support | 0.8576 | 0.8576 | 1.346 |
- Stock Market
- Stocks
- GRI Stock
- Charts GRI BIOPAR
Select your edition
All financial news and data tailored to specific country editions
